U.S. Markets close in 1 hr 8 mins

Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene

Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting

Believes the Proposed Merger with Celgene is Not in the Best Interests of Bristol-Myers Shareholders and Urges All Shareholders to Reject the Proposed Transaction

NEW YORK, March 19, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(BMY), today announced that it has issued an investor presentation opposing the Company's proposed merger with Celgene Corporation (the "Merger"), which it believes is ill-advised and not in the best interests of Bristol-Myers shareholders.  Starboard also announced today that it has mailed definitive proxy materials and a BLUE proxy card in connection with the Company's Special Meeting of Shareholders scheduled to take place on April 12, 2019, at which Bristol-Myers shareholders will vote on the issuance of shares of Bristol-Myers common stock pursuant to the Merger.

The investor presentation and definitive proxy materials are available for viewing at www.shareholdersforbristol.com.

About Starboard Value LP
Starboard Value LP is a New York-based investment adviser with a focused and differentiated fundamental approach to investing primarily in publicly traded U.S. companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders.

Investor contacts:
Peter Feld, (212) 201-4878
Gavin Molinelli, (212) 201-4828

Okapi Partners
Bruce H. Goldfarb/Patrick McHugh
(212) 297-0720




View original content:http://www.prnewswire.com/news-releases/starboard-issues-investor-presentation-opposing-bristol-myers-squibbs-ill-advised-proposed-acquisition-of-celgene-300814683.html